Autologous Natural Killer T Cells Infusion for the Treatment of Cancer

Inclusion Criteria

• •Life expectancy of ≥ 24 weeks as measured by the Eastern Cooperative Oncology Group (ECOG) performance status.
• •Subjects must present with one of the following disease pathologies: Breast Cancer, Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer, Pancreatic Cancer, Colon Cancer or Prostate Cancer
• •The pathology must be an assessable disease (measurable by CT scan or MRI) that is refractory to standard treatments (e.g., chemotherapy, radiation, etc.)
• •Negative for hepatitis B, hepatitis C, HIV, and CMV.
• •Subjects must present with leukocyte counts above 3,000/μL and platelet counts above 100,000/ μL.
• •Subjects must present with minimum hemoglobin levels of 10.
• •If female, subject is surgically sterile (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), post menopausal (no menses \>12 months), or using a high-efficiency method of contraception such as implant, injectable, combination oral contraceptive, intrauterine device (IUD) or sexual abstinence, or has a vasectomized partner.
• •If female of childbearing potential, subject is not pregnant, breast-feeding or planning a pregnancy during the study, and has a negative pregnancy test on screening visit.
• •Able to comprehend and sign an informed consent document and comply with the requirements of the study.